Xing et al. also conducted a meta-analysis of six RCTs [41], involving 309 patients with NAFLD and T2DM and concluded that SGLT-2 inhibitors significantly reduced ALT and liver fat content, consistent with our research results, confirming the reliability of our research results. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.